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Abstract
Background: Systemic lupus erythematosus (SLE) is a genetically complex rheumatic disease characterized by
heterogeneous clinical manifestations of unknown etiology. Recent studies have suggested the existence of a
genetic basis for SLE heterogeneity. The objective of the present study was to identify new genetic variation
associated with the clinically relevant phenotypes in SLE.
Methods: A two-stage pathway-based approach was used to identify the genetic variation associated with the main
clinical phenotypes in SLE. In the discovery stage, 482 SLE patients were genotyped using Illumina Human Quad610
microarrays. Association between 798 reference genetic pathways from the Molecular Signatures Database and 11 SLE
phenotypes was tested using the set-based method implemented in PLINK software. Pathways significantly associated
after multiple test correction were subsequently tested for replication in an independent cohort of 425 SLE patients.
Using an in silico approach, we analyzed the functional effects of common SLE therapies on the replicated genetic
pathways. The association of known SLE risk variants with the development of the clinical phenotypes was also analyzed.
Results: In the discovery stage, we found a significant association between the vascular endothelial growth factor (VEGF)
pathway and oral ulceration (P value for false discovery rate (PFDR) < 0.05), and between the negative regulation signaling
pathway of retinoic acid inducible gene-I/melanoma differentiation associated gene 5 and the production of antinuclear
antibodies (PFDR < 0.05). In the replication stage, we validated the association between the VEGF pathway and oral
ulceration. Therapies commonly used to treat mucocutaneous phenotypes in SLE were found to strongly influence VEGF
pathway gene expression (P = 4.60e-4 to 5.38e-14). Analysis of known SLE risk loci identified a strong association between
PTPN22 and the risk of hematologic disorder and with the development of antinuclear antibodies.
Conclusions: The present study has identified VEGF genetic pathway association with the risk of oral ulceration in SLE.
New therapies targeting the VEGF pathway could be more effective in reducing the severity of this phenotype. These
findings represent a first step towards the understanding of the genetic basis of phenotype heterogeneity in SLE.
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Background
Systemic lupus erythematosus (SLE) is a disabling multi-
system rheumatic disease with substantial epidemiological
variation [1]. SLE is characterized by the dysregulation of
the immune system and high phenotypical diversity [2].
This phenotypical heterogeneity includes a wide range of
clinical manifestations that are exemplified by the current
use of multiple clinical phenotypes as criteria to diagnose
the disease [3]. So far, however, little is known about the
causes of this phenotypic variation. Understanding the
molecular mechanisms associated with the pathogenesis
of SLE phenotypes could therefore be of high relevance to
develop more efficient therapeutic approaches and pre-
ventive strategies.
SLE is characterized by a strong genetic component,
with a sibling recurrence rate (λs) of 8–29 and estimated
heritability of approximately 66% [4]. To date, nine
genome-wide association studies (GWAS) of SLE risk
have been performed in European and Asian populations
[5]. Together these studies have led to the identification
of >40 loci associated with SLE susceptibility. Despite
this extraordinary success, there is still a lack of under-
standing of the genetic variation that is relevant for the
development of specific phenotypes within the disease.
There is evidence, however, that the main clinical phe-
notypes in SLE aggregate in families [6], suggesting a
genetic basis underlying disease heterogeneity.
To date, only a few candidate gene studies have been
performed to uncover the genetics of clinical heterogen-
eity in SLE [7]. These studies have identified immunity-
related genes associated with clinically relevant SLE phe-
notypes [8]. From these, the most significant associations
have been detected between renal disorder and genetic
variation in the ITGAM and STAT4 genes, which have
been also associated with discoid rash and oral ulceration,
respectively [9, 10]. Other significant findings include the
association between renal disorder and TNFSF4, malar
rash and FCGR2A and hematological disorder and vari-
ation in the IL21 gene. So far, however, the genetic compo-
nent for most SLE phenotypes has been only partially
explained. Therefore, the analysis of genetic variation at a
genome-wide scale is needed to identify additional vari-
ation associated with SLE clinical heterogeneity.
Complex traits like disease risk or clinical phenotypes
have been shown to be caused by multiple genes of small
effect size [11]. The identification of these small-effect
genes is currently one of the major challenges in the
characterization of the genetic background for disease
phenotypes [12]. Importantly, single-marker GWAS do
not allow the identification of genetic variants with small
effect sizes, unless extremely large sample sizes are used
[13]. In this common type of GWAS, a large number of
markers are tested for association and, consequently,
stringent significance thresholds are applied, which makes
the identification of small-effect variants very difficult
[14]. In addition, single-marker GWAS ignore the joint
contribution of multiple genes that act coordinately in the
same biological process [15]. The characterization of the
genetic basis of many complex traits will therefore require
the development of new powerful methods that are able
to leverage biological knowledge and efficiently integrate
the evidence from multiple loci with moderate to small ef-
fect sizes.
Recently, novel statistical methodologies that are able
to test genetic risk associations at the pathway level have
been developed [16]. Pathway-based approaches test
whether sets of functionally related genes are jointly as-
sociated with a particular phenotype [17]. This method-
ology strongly reduces the number of association tests
and, therefore, it can substantially increase the power to
identify new genetic variation compared to single-
marker GWAS [18]. The genome-wide pathway analysis
(GWPA) has been recently used to characterize the gen-
etic basis of several complex diseases like cancer [19].
Very recently, using the GWPA approach we have iden-
tified new genetic variation associated with psoriasis, an
autoimmune disease of the skin [20]. This result con-
firms the utility of GWPA in the study of the genetics of
autoimmune diseases.
To gain a better understanding of the genetic basis
underlying phenotype heterogeneity in SLE we have per-
formed, for the first time, a GWAS of clinical pheno-
types using the GWPA approach. In this study we have
analyzed a discovery cohort of 482 SLE patients of Euro-
pean ancestry to determine the association between 798
reference biological pathways and the main clinical phe-
notypes of SLE represented that are used as diagnosis
criteria. Using an independent cohort of 425 SLE pa-
tients from the same ancestry, we have then performed a
validation study of the most significant genetic pathways.
Based on these results, we have performed an in silico
validation analysis to evaluate the functional impact of
drugs commonly used to treat the associated phenotype.
Our findings provide new insights into the biological
mechanisms associated with clinical phenotypes of SLE.
Methods
Study population
In the discovery stage, a total of 482 SLE patients were
recruited. SLE patients were collected from the out-
patient clinics of the rheumatology departments of 15
Spanish University Hospitals belonging to the Immune-
Mediated Inflammatory Disease (IMID) Consortium
[21]. All patients were diagnosed by a rheumatologist.
Only those patients with SLE that fulfilled ≥4 of the
1982 revised American College of Rheumatology (ACR)
diagnosis criteria were included in the present study [3].
All patients included in this study were >16 years old at
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the time of sample collection and had >3 years of evolu-
tion from the diagnosis date. SLE patients with psoriasis,
inflammatory bowel disease (Crohn’s disease or ulcera-
tive colitis) or other rheumatic diseases like rheumatoid
arthritis, or multiple sclerosis were excluded from the
study. All SLE patients were Caucasian European with
all four grandparents born in Spain.
In the validation stage, an independent cohort of 425
SLE patients was used to replicate the genetic pathways
that were significantly associated with the SLE pheno-
types in the discovery stage. All patients from the valid-
ation cohort fulfilled the ACR diagnostic criteria for SLE
and were also collected from the IMID Consortium, fol-
lowing the same inclusion and exclusion criteria as for
the discovery cohort. All the procedures were followed
in compliance with the principles of the Declaration of
Helsinki.
The main epidemiological and clinical variables of the
discovery and validation cohorts are summarized in
Table 1. The distribution of each variable was compared
between the discovery and validation cohorts using Fish-
er’s exact test or Student’s t test for categorical and
quantitative variables, respectively.
SLE phenotypes
The diagnosis of SLE is of major importance to guide
both the disease classification and the patient therapy
[22]. Given the high phenotypic heterogeneity of SLE, in
order to analyze the most relevant clinical manifestations
for disease diagnosis we defined the SLE phenotypes
according to the established ACR diagnostic criteria for
SLE [3]. Consequently, the 11 SLE phenotypes represented
by the ACR diagnostic criteria were analyzed using the
GWPA approach. These criteria include malar rash, dis-
coid rash, photosensitivity, oral ulcers, arthritis, serositis,
renal disorder, neurologic disorder, hematologic disorder,
immunologic disorder and antinuclear antibodies. The
distribution of each clinical phenotype in the discovery
and replication cohorts is shown in Table 1.
DNA extraction and genome-wide genotyping in the
discovery and validation patients
In the discovery stage, the genome-wide genotyping of the
482 SLE patients was performed using the Illumina
Quad610 Beadchips (Illumina, San Diego, CA, USA) at the
Centro Nacional de Genotipado (CeGen, Madrid, Spain).
The genotyping quality control analysis was performed
using PLINK software (Additional file 1: Figure S1) [23]. To
evaluate the presence of potential population stratification
in the SLE patient cohorts, we used the principal compo-
nent analysis (PCA) implemented in the EIGENSOFT
(v4.2) software [24]. Using the first 10 PCs of variation over
10 iterations we identified 14 samples showing an outlier
genetic background and were excluded from downstream
analysis (Additional file 1: Figure S1). After the quality con-
trol analysis, a final dataset of 507,051 single nucleotide
polymorphisms (SNPs) and 395 SLE patients was available
for the GWPA.
The validation of the two genetic pathways associated
with SLE in the discovery stage required the genotyping
Table 1 Main epidemiological and clinical features of the discovery and validation patient cohorts
Clinical and epidemiological variablesa Discovery cohort Validation cohort P
Genetic background CEU CEU -
Number of individuals (N) 482 425 -
Gender (% females) 443 (91.91%) 398 (93.65%) 0.37
Average age at onset (m ± SD) 33.50 ± 14.09 32.39 ± 13.32 0.22
Malar rash (N+/N-) 185/174 183/175 1.00
Discoid rash (N+/N-) 46/313 49/309 0.74
Photosensitivity (N+/N-) 191/168 173/185 0.20
Oral ulcers (N+/N-) 153/206 172/186 0.15
Arthritis (N+/N-) 275/84 267/91 0.54
Serositis (N+/N-) 110/249 122/236 0.34
Renal disorder (N+/N-) 120/239 108/250 0.38
Neurologic disorder (N+/N-) 25/334 35/293 0.10
Hematologic disorder (N+/N-) 341/18 337/21 0.63
Immunologic disorder (N+/N-) 289/70 292/66 0.77
Antinuclear antibodies (N+/N-) 346/13 347/11 0.84
Abbreviations: CEU Caucasian European, M mean, N sample size, N+ sample size of positive individuals for the clinical variable, N- sample size of negative
individuals for the clinical variable, P P value, SD standard deviation
aNumber of individuals shown in the table represents the total number of patients that were initially recruited for the present study. Conversely, the sample size
of positive/negative individuals for the indicated clinical phenotype represents the final number of SLE patients having data on both genotype and phenotype
available for association analysis
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and analysis of a total 1347 SNPs. Given the large num-
ber of variants to be tested and the utility of genome-
wide data for accurate genetic ancestry identification,
the 425 SLE patients in the validation cohort were geno-
typed using the same microarray platform. Genotyping
for the validation stage was performed at the HudsonAl-
pha Institute for Biotechnology (Huntsville, AL, USA).
The same quality control analysis as in the discovery
stage was performed (Additional file 1). A total of 394
SLE patients and all 1347 SNPs from the two genetic
pathways passed the quality control and were available
for the pathway-based analysis of the validation stage.
Analysis of association between established SLE risk SNPs
and SLE phenotypes
Genetic variants associated with SLE risk
The list of established genetic variants (P < 5e-8) for SLE
risk was obtained from a recent GWAS meta-analysis in a
case-control cohort of European ancestry [5]. A total of 43
genetic variants associated with SLE risk were identified
and selected for the analysis of association with SLE clin-
ical phenotypes (Additional file 1: Table S6).
Imputation of genetic variants associated with SLE risk
From the established autosomal SLE risk SNPs (N = 41
SNPs), the genetic variants that were not directly geno-
typed by the GWAS Quad610 genotyping array (N = 17
SNPs) were imputed (Additional file 1). Those SNPs that
did not pass the stringent imputation quality control filter
(N = 1 SNP, information quality metric <0.8) were ex-
cluded from the study. Therefore, after excluding two
non-autosomal variants and a low-quality imputed SNP, a
total of 40 from the initial 43 established SLE risk SNPs
were finally available for analysis of association with SLE
phenotypes in the discovery cohort. In the validation co-
hort, the same procedure was followed to obtain the geno-
types of the risk variants to be tested for replication.
Statistical association analysis
The statistical association analysis between the allele
dosage of the established SLE risk SNPs and the SLE
clinical phenotypes was performed using the logistic re-
gression model implemented in the SNPTEST v2 soft-
ware (Oxford, UK) [25]. In this model, the allele dosage




Pr G ¼ gð Þ  g
Where g represents each genotype of a particular gen-
etic variant i and Pr(G = i) is the marginal posterior
probability obtained by imputation. The allele dosage
takes values between 0 and 2. SLE patients without
phenotypical data available for the phenotype analyzed
were excluded from the association analysis. Finally, the
P values obtained from the discovery and replication
stages were combined using the METAL software [26].
GWPA
GWPA method
The gene-set analysis, also referred to as pathway ana-
lysis, is a very powerful methodology to analyze the gen-
etic architecture of complex diseases using GWAS data
[27, 28]. An important advantage of this approach is that
the hypothesis space is significantly reduced compared
to single-marker GWAS. While extremely large number
of markers (>500,000 to several millions) are independently
tested for association in single-marker GWAS, the number
of simultaneous tests is several orders of magnitude lower
in pathway-based GWAS (typical range 500–2000 path-
ways). Consequently, the threshold for significance is much
less stringent than the consensus threshold used for single-
marker GWAS (P < 5e-8) [18, 27]. In addition, pathway-
based studies integrate the effects of multiple genetic risk
variants that participate in the same biological processes.
For these reasons, pathway-based studies can have high
statistical power to discover new susceptibility genetic
variants provided that they operate within the analyzed
pathways.
In the present study, the GWPA was performed using the
set-based test implemented in the PLINK software as de-
scribed previously [20, 23]. Compared to other methods,
this set-based test uses genotype data to estimate pathway
association instead of P values for significance. Importantly,
this approach accounts for the linkage disequilibrium be-
tween SNPs and therefore avoids an increase in false posi-
tive results due to genes with multiple, highly correlated
markers. For each pathway, independent SNPs are first
identified (linkage disequilibrium of r2 < 0.2 here), and from
these an average statistic is calculated. Finally, the statistical
significance of the pathway is computed using permutation,
thereby efficiently correcting by the number of SNPs within
the pathway (Additional file 1). As described for the analysis
of association with established SLE risk SNPs, those pa-
tients with missing data for the phenotype tested for associ-
ation were excluded from the analysis. In order to account
for multiple testing, the false discovery rate (FDR) method
was used. The corrected empirical P values from the dis-
covery and validation stages were combined using Fisher’s
method.
Gene set definition
Reference biological pathway annotation databases Bio-
Carta, Kyoto Encyclopedia of Genes and Genomes
(KEGG) and Reactome were used for the present study
[29]. A total of 217, 186 and 674 curated biological path-
ways from the Biocarta, KEGG and Reactome databases,
respectively, were included, respectively (5th October
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2015). Very small uninformative pathways (i.e. <=15
genes) were excluded from the analysis. As described
previously, we also excluded large genetic pathways
(i.e. >300 genes) [17]. The SNP-gene mapping was per-
formed using the NCBI RefSeq database release 63 (12th
October 2015) and an SNP-gene distance window of 20
Kb [30]. The final gene set used for the present GWPA
was composed of 211,724 SNPs mapping to 798 different
pathways. The list of genetic pathways included in the
GWPA is shown in Additional file 1: Table S7.
In silico analysis of VEGF pathway genes after treatment
with topical immunotherapies for cutaneous SLE
In the GWPA, we identified significant genetic association
between oral ulceration and the VEGF pathway. The
VEGF pathway plays a crucial role in angiogenesis, and
there is increasing evidence supporting the implication of
this biological process in the pathogenesis of SLE cutane-
ous phenotypes [31]. These disease phenotypes are com-
monly treated with steroid and non-steroid topical
immunotherapies in SLE [32, 33]. Consequently, we hy-
pothesized that the topical immunotherapies prescribed
for cutaneous SLE mediate their therapeutic effect in this
tissue through the VEGF pathway and, therefore, should
induce significant transcriptional changes in the pathway
genes. In order to test this hypothesis, we used transcrip-
tional data from microarray experiments in the NCBI
Gene Expression Omnibus microarray database (GEO,
https://www.ncbi.nlm.nih.gov/geo/). In this database, we
searched for whole genome expression profiling datasets
generated from cutaneous/mucocutaneous human sam-
ples or cell cultures (5 November 2015). From these, we
looked for tissue or cell cultures treated with any of the
common steroid and non-steroid topical immunother-
apies most widely used in SLE (Additional file 1). We
found a total of three datasets analyzing the trans-
criptional variation after treatment with four common
immunotherapies: betamethasone valerate and pimecroli-
mus (GSE32473), diphencyprone (GSE52360) and imiqui-
mod (GSE68182). The first two transcriptional datasets
(i.e. GSE32473 and GSE52360) were obtained from
skin biopsies and the latter (GSE68182) from an in
vitro study on vaginal mucosal cells (i.e. cell line Vk2/
E6E7). For each gene expression dataset, we per-
formed quality control analysis and subsequent
normalization on the log2 scale using the quantile
normalization method. The analysis of differential ex-
pression of the VEGF pathway genes between treated
and non-treated samples was performed using Stu-
dent’s t test. The statistical significance of the global
perturbation of the VEGF pathway was assessed using
the binomial test. All analyses were performed using
the R statistical software [34].
Results
Phenotypic characterization of the studied cohorts
The epidemiological and phenotypical characteristics
of the discovery and replication SLE populations are
shown in Table 1. There were no significant differences
between the discovery and replication cohorts in the distri-
bution of the epidemiological and phenotypical variables
(P > 0.05, Table 1).
Identification of SLE risk genetic variants associated with
SLE phenotypes
In the discovery stage, we found that 19 out of the 43
SNPs previously associated with SLE risk were also sig-
nificantly associated with one or more clinical pheno-
types (PDiscovery < 0.05, Table 2). The association results
between each established genetic variant and SLE
phenotype are summarized in Additional file 1: Table S1.
However, in the independent validation cohort, only the
association between PTPN22 and hematologic disorder
(PReplication = 0.043, PCombined = 8.25e-4) and between
PTPN22 and the production of antinuclear antibodies
(PReplication = 0.028, PCombined = 0.001) were significantly
replicated. Combining the statistical evidence from the
two cohorts, an additional seven loci were found to be
associated with SLE phenotypes at the nominal level
(PCombined < 0.05, Table 2).
Identification of genetic pathways associated with SLE
phenotypes
In the GWPA, two genetic pathways were found to be
significantly associated with an SLE phenotype after
multiple test correction (P value for false discovery rate
(PFDR) < 0.05, Table 3). The VEGF pathway was associ-
ated with the presence of oral ulcers (PFDR = 0.044) and
the RIG-I/MDA5 negative regulation signaling pathway
was associated with the production of antinuclear anti-
bodies (PFDR = 0.016). The results for analysis of associ-
ation between each genetic pathway and SLE phenotype
are shown in Additional file 1: Table S2.
Using the independent validation cohort, the associ-
ation between the VEGF genetic pathway and oral ulcers
in SLE was significantly replicated (PFDR = 0.026, Table 3).
The details of association between the VEGF pathway
and oral ulcers are shown in Additional file 1: Table S3.
Perturbation of the VEGF genetic pathway by current
therapies for cutaneous SLE
Topical immunotherapies are drugs commonly used to
treat cutaneous phenotypes of SLE like oral ulceration.
Given the observed genetic association between oral
ulcers and VEGF pathway, we performed an in silico
analysis to evaluate the effect of four current topical im-
munotherapies on the expression of its constituent
genes. Using whole genome expression datasets from
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patients and relevant cell types treated with these ther-
apies, we found that three out of the four analyzed
drugs significantly perturb the expression of VEGF
pathway genes (Fig. 1, Additional file 1: Table S4). A
total of 16, 12 and 7 genes out of the 29 genes from the
VEGF pathway were significantly differentially expressed
after imiquimod (P = 5.38e-14), betamethasone valerate
(P = 5.69e-9) and diphencyprone (P = 4.59e-4) treatment,
respectively (Additional file 1: Table S5).
Discussion
One of the major challenges in the pathogenesis of SLE
is to understand the biological mechanisms responsible
for its phenotypic heterogeneity. Although single-marker
Table 2 SLE risk SNPs association with clinical phenotypes
SNP Chr Pos Gene RA Phenotype PD PV PC OR (CI, 95%)
rs2476601a 1 114377568 PTPN22 A Hematologic disorder 0.0039 0.0433 5.20e-4 9.488 (1.310-68.726)
Antinuclear antibodies 0.0146 0.0281 0.0011 0.168 (0.004-0.990)
rs704840 1 173226195 TNFSF4 G Renal disorder 0.0407 0.9210 0.1290 1.199 (0.941-1.527)
rs3024505 1 206939904 IL10 T Arthritis 0.0325 0.1540 0.0170 1.557 (1.091-2.221)
rs3768792 2 213871709 IKZF2 C Photosensitivity 0.0437 0.3320 0.4580 0.893 (0.674-1.184)
Hematologic disorder 0.0319 0.1880 0.0143 0.507 (0.301-0.855)
rs9311676 3 58470351 ABHD6,PXK C Oral ulcers 0.0338 0.7960 0.9210 0.832 (0.674-1.028)
rs564799 3 159728987 IL12A C Discoid rash 0.0411 0.1410 0.6853 0.942 (0.674-1.316)
rs1270942 6 31918860 MHC class III C Arthritis 0.0138 0.6670 0.0407 1.530 (1.010-2.346)
rs9462027 6 34797241 UHRF1BP1 A Malar rash 0.0263 0.1730 0.0137 1.333 (1.071-1.660)
Oral ulcers 0.0251 0.8950 0.0933 1.210 (0.971-1.508)
rs6932056 6 138242437 TNFAIP3 C Serositis 0.0193 0.8140 0.1364 1.580 (0.898-2.781)
rs4917014 7 50305863 IKZF1 T Oral ulcers 0.0280 0.1550 0.5821 0.944 (0.753-1.184)
rs2663052 10 50069395 WDFY4 C Neurologic disorder 0.0370 0.1590 0.6311 0.963 (0.662-1.401)
rs4948496 10 63805617 ARID5B C Malar rash 0.0331 0.4580 0.3258 1.116 (0.906-1.375)
Photosensitivity 0.0202 0.9480 0.0911 1.203 (0.977-1.483)
rs2732549 11 35088399 CD44 T Immunologic disorder 0.0163 0.9910 0.0907 1.277 (0.976-1.670)
rs7941765 11 128499000 ETS1,FLI1 C Arthritis 0.0072 0.0701 0.0015 1.470 (1.151-1.877)
rs10774625 12 111910219 SH2B3 A Serositis 0.0207 0.0756 0.0038 0.715 (0.571-0.895)
Renal disorder 0.0423 0.6410 0.0773 0.814 (0.650-1.018)
Immunologic disorder 0.0051 0.8190 0.0321 0.738 (0.566-0.964)
rs1059312 12 129278864 SLC15A4 C Serositis 0.0253 0.2370 0.0156 1.321 (1.053-1.658)
rs4902562 14 68731458 RAD51B A Renal disorder 0.0130 0.8670 0.1010 0.834 (0.664-1.047)
rs2941509 17 37921194 IKZF3 A Antinuclear Antibodies 0.0304 0.0413 0.4943 0.676 (0.237-1.930)
rs2304256 19 10475652 TYK2 C Arthritis 0.0298 0.7690 0.1841 0.826 (0.622-1.096)
A total of 19 SLE risk genetic variants were significantly associated with different systemic lupus erythematosus (SLE) phenotypes in the discovery stage. From
these, the association between PTPN22 and hematologic disorder and between PTPN22 and the production of antinuclear antibodies (a) were significantly
replicated in the validation cohort. Combining the statistical evidence from the two cohorts, seven additional genetic variants were found to be nominally
associated with SLE phenotypes (shown in bold). Abbreviations: SNP single-nucleotide polymorphism, Chr chromosome, Pos SNP base pair in build GRCh37/hg19,
RA disease risk allele, PD P value discovery cohort, PV P value validation cohort, PC P value combined, OR odds ratio according to the allele associated with disease
risk, CI confidence interval (95%)
Table 3 Genetic pathways associated with the SLE phenotypes in the discovery stage
Pathway Phenotype #Genes SNPs PD FDR D PV FDR V PC
RIG-I/MDA5 negative
regulation signaling
Antinuclear antibodies 31 464 2.00e-5 0.016 0.234 0.234 -
VEGFa Oral ulcers 29 883 5.58e-5 0.044 0.013 0.026 2.08e-5
Two genetic pathways were significantly associated with systemic lupus erythematosus (SLE) phenotypes in the discovery stage
Abbreviations: SNP single-nucleotide polymorphism, PD P value discovery cohort, FDRD false discovery rate discovery cohort, PV P value validation cohort, FDRV false
discovery rate validation cohort, PC P value combined
aThe association between the vascular endothelial growth factor (VEGF) pathway and oral ulcers was significantly replicated in the validation cohort
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GWAS have successfully identified a large number of
genetic variants associated with SLE risk, the genetic
basis of SLE phenotypes has so far been analyzed only in
a few candidate gene studies. In order to identify new
genetic variation, we have here performed the first
GWAS on SLE phenotypes using a pathway-based
approach. Using a discovery cohort of individuals with
European ancestry and a validation cohort with the same
ancestry, we have identified and validated the association
between VEGF genetic pathway and oral ulcers, a com-
mon manifestation of SLE. The results of this study pro-
vide new insights into the genetic basis and the biological
mechanisms associated with the clinical heterogeneity of
SLE.
The VEGF pathway is a network of genes that are in-
volved in the transduction of different intracellular
signals and act coordinately to modulate inflammatory
and angiogenic processes [35, 36]. The dysregulation of
angiogenesis has been described as an important bio-
logical mechanism in the pathogenesis of SLE [37]. In
particular, there is growing evidence that angiogenesis is
also involved in the development of skin manifestations
in SLE patients [38, 39]. The serum levels of VEGFA
protein itself have been suggested as a useful marker for
disease activity monitoring in SLE patients [40]. Import-
antly, the serum levels of VEGFA have also been found
to be significantly elevated in SLE patients with cutane-
ous manifestations [41]. Despite this clinical evidence,
the VEGF pathway had not been previously associated
with SLE at the genetic level. Our study provides the
first evidence of a genetic association between the VEGF
pathway and oral ulceration in SLE.
Fig. 1 Vascular endothelial growth factor (VEGF) pathway perturbation after topical immunotherapy. Network representation of VEGF genes according
to the differential gene expression after treatment with common topical immunotherapies: imiquimod (a), betamethasone valerate (b), diphencyprone
(c) and pimecrolimus (d). Genes are represented as nodes and are connected by edges according to experimental or computational evidence of
interaction between their encoded proteins. The diameter of each node is proportional to the significance of differential expression, with significant
genes (P < 0.05) in red and non-significant genes (P≥ 0.05) in blue
Aterido et al. Arthritis Research & Therapy  (2017) 19:138 Page 7 of 11
Oral ulcers are frequently chronic mucocutaneous le-
sions that affect up to 54% of patients with SLE [42, 43].
This clinical manifestation is characterized by high angio-
genic activity and a loss of the epithelial and connective
tissue in the oral mucosa [44, 45]. Accordingly, anti-
angiogenic therapies like thalidomide have been suggested
to promote oral ulcer healing and to control ulcer recur-
rence [46, 47]. From a clinical perspective, oral ulceration
has been associated with an increase in the disease activity
and a worse prognosis in SLE [48, 49]. The early detection
of oral ulcers is therefore highly valuable as it contributes
to an earlier diagnosis of SLE and, consequently, to faster
initiation of treatment.
The genetic association identified in this study is con-
sistent with previous evidence from other ulcer-related
diseases like Behçet disease (BD), recurrent aphtosus ul-
ceration (RAU) and gastroduodenal ulcers. BD is an in-
flammatory disorder characterized by an extremely high
frequency of oral ulcers (>95%) [50]. Clinical evidence
suggests that VEGF cytokine could be directly implicated
in the formation of oral ulcers in BD [51]. In RAU, the
most common oral mucosal disease, the salivary levels of
VEGF have been also associated with oral ulceration [52].
Finally, genetic variation in the VEGF gene has been also
associated with the risk of developing gastroduodenal
ulcers [53]. Evidence from these studies implicates angio-
genesis in the pathophysiological development of oral ul-
cers, at both the genetic and at the functional level.
Accordingly, the genes in the VEGF pathway are strong
candidates for susceptibility in diseases with a high preva-
lence of oral ulcers like BD or RAU. Future studies aimed
at testing the association between VEGF pathway genes
and these diseases are therefore warranted.
Topical steroid and non-steroid immunotherapies have
been successfully used for the treatment of the cutane-
ous manifestations in SLE. However, topical immuno-
therapies are not exempt from side effects, including
skin atrophy or telangiectasias with corticosteroids and
the exacerbation of the inflammatory processes with
non-steroid immunotherapies like imiquimod [32]. In
this study, we have demonstrated that topical steroid
and non-steroid immunomodulators significantly affect
the expression of the VEGF pathway genes. The results
of this in silico analysis indicate that the VEGF genetic
pathway could be a key mediator of the benefits of top-
ical immunotherapy to reduce oral ulceration. Therefore,
our findings suggest that the VEGF pathway is a relevant
source of new drug targets for oral ulceration that could
allow more specific treatment while reducing the un-
desirable side effects of current therapies. In order to
confirm the VEGF pathway as new source for drug dis-
covery in the treatment of SLE oral ulceration, further
prospective studies using oral ulcer samples from SLE
patients are clearly needed.
In the present study, we have also identified and vali-
dated the association between SLE risk locus PTPN22
and the production of antinuclear antibodies and with
the presence of a hematologic disorder. It is the first
time that this coding SNP (rs2476601) has been associ-
ated with the development of hematologic disease in
SLE. A previous study reported a non-significant trend
for association between PTPN22 and antinuclear anti-
body positivity [54]. The results from our study provide
the evidence to confirm the association between this
susceptibility gene and the production of a common
autoantibody in SLE. Also, the previously identified asso-
ciation between genetic variation in the TNFSF4 gene
and renal disorder was replicated in the discovery cohort
[9]. Conversely, the reported association between renal
disorder and ITGAM and STAT4 genes was not repli-
cated. The renal disorder phenotype encompasses differ-
ent clinical manifestations (e.g. persistent proteinuria or
cellular casts) and, therefore, differences in frequencies
in any of these sub-phenotypes could have prevented the
replication. Additional studies performing specific ana-
lysis of association for each renal disease subtype could
help to further refine this genetic association. Oral ulcer-
ation was also previously found to be associated with
variation in STAT4. This association was not replicated
in the present single-marker analysis. The lack of repli-
cation could be explained by the comparatively smaller
sample size of our study cohorts and by the small effect
size reported for the association (OR ~ 1.12). For ex-
ample, in the European cohort, STAT4 association was
not statistically significant despite analyzing >4,000 indi-
viduals [9]. Finally, after combining both patient cohorts,
we also found seven other SLE risk loci - IL10, IKZF2,
MHC class III, UHRF1BP1, ETS1-FLI1, SH2B3 and
SLC15A4 - to be nominally associated with different
phenotypes. These also represent new genetic associa-
tions with SLE heterogeneity. Further studies using inde-
pendent cohorts of phenotypically well-characterized
SLE patients like the present one are needed to corrob-
orate these associations.
GWPA represents a new and powerful approach to
identify genetic variation associated with complex phe-
notypes. However, this study has limitations. First, the
sample size of the discovery and replication cohorts is
moderate compared to recent case-control GWAS and
this could have led to missed pathway associations with
SLE clinical phenotypes. Second, the statistical power to
detect significant associations is lower for those clinical
phenotypes with more extreme frequencies (e.g. 7% of
SLE patients have a neurologic disorder). Therefore, lar-
ger cohorts of well-characterized SLE patients will be
needed to identify additional genetic variation associated
with clinical phenotypes. Finally, the GWPA method-
ology also has intrinsic limitations, mainly related to the
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current knowledge of biological processes and subse-
quent definition of the pathways [55]. For many human
genes, the functional annotation is far from complete,
which precludes their mapping to reference biological
pathways. Also, genomic variation located far from the
transcribed region itself could be relevant for the regulation
of the gene expression. Conversely, variants within genes
could be influencing the activity of other distant genes or
genes in other chromosomes (i.e. trans-regulation). With
the increase in knowledge of genomic regulation [56], the
mapping of SNPs to their functionally related genes will
clearly improve. Consequently, the integration of this
knowledge into GWPA will likely increase the power of this
approach to identify new pathways associated with human
diseases.
Conclusions
In conclusion, we have performed, for the first time, a
genome-wide association analysis to identify genetic risk
factors for the main phenotypes in SLE. To do this, we have
used a pathway-based analysis approach. Using this ap-
proach, we have identified and validated the association be-
tween the VEGF genetic pathway and the presence of oral
ulcers in SLE. These findings show the existence of a gen-
etic basis underlying SLE heterogeneity that is independent
from the genetic component associated with disease risk.
The results of the present study could contribute to the de-
velopment of more efficient therapies to treat cutaneous
manifestations of SLE in the near future.
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